Odile Belzunce

Odile Belzunce (senior executive) discloses dealings in Innate Pharma to AMF. Over a trading history stretching from 4 November 2022 to 31 December 2025, the count stands at 3 filings.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.

Most recently, on 5 January 2026, the filings show a share grant in Innate Pharma. Filings reach the AMF feed a median of 20 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.